MEGAKARYOCYTES SUPPORT THE INTEGRITY OF BONE MARROW (BM) VASCULAR NICHES AND ATTRACT METASTATIC TUMOUR CELLS TO THE BM IN MURINE MODELS OF METASTASIS AND IN PATIENTS WITH CARCINOMA
Psaila B. et al, (2010), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 477 - 478
A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
Molife LR. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
Zweifel M. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Macaulay VM. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Selective inhibition of proliferating endothelial cells: A phase I study of the novel organoarsenical compound GSAO in patients with advanced solid tumors
Kumaran G. et al, (2010), JOURNAL OF CLINICAL ONCOLOGY, 28
Non-cancer medications for patients with incurable cancer: time to stop and think?
Hall PS. et al, (2010), Br J Gen Pract, 60, 243 - 244
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
Helfrich I. et al, (2010), J Exp Med, 207, 491 - 503
A reply to evidence-based radiation oncology: oesophagus.
Gillies RS. et al, (2010), Radiother Oncol, 94, 387 - 388
Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.
Lord SR. et al, (2010), Clin Oncol (R Coll Radiol), 22, 107 - 113
The vascular phenotype, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma
Helfrich I. et al, (2010), EUROPEAN JOURNAL OF CELL BIOLOGY, 89, 44 - 44
Concomitant medications in cancer patients: should we be more active in their management?
Lord S. et al, (2010), Ann Oncol, 21
Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.
Haynes RJ. et al, (2010), Nephrol Dial Transplant, 25, 419 - 426
Resistance to anti-angiogenic therapy is directed by vascular phenotype, vessel stabilization and maturation in malignant melanoma
Helfrich I. et al, (2010), EXPERIMENTAL DERMATOLOGY, 19, 213 - 213
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.
Watson AJ. et al, (2010), Clin Cancer Res, 16, 743 - 749
Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
Gillies RS. et al, (2010), European Radiology, 1 - 7
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
Garbe C. et al, (2010), Eur J Cancer, 46, 270 - 283
Are we representing the true population in oncology trials?
Lord SR. et al, (2009), Annals of Oncology, 20
Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases.
Psaila B. et al, (2009), Blood, 114, 4777 - 4783